NeoGenomics has signaled a robust revenue outlook for 2026, projecting a range of $797 million to $803 million. This optimistic forecast follows the recent PanTracer Liquid MolDX approval, a development expected to significantly contribute to the company’s financial performance.
First Quarter Performance Exceeds Expectations
The company reported strong first-quarter results, with total revenue reaching $186.7 million, an 11% increase year-over-year. This figure surpassed the company’s own guidance. “Total revenue for Q1 was $186.7 million, representing 11% growth year-over-year, exceeding our guidance,” stated CEO Anthony Zook. The company also achieved an adjusted EBITDA of $9 million, with clinical revenue contributing $171 million to the quarter’s top line.
Future Growth Drivers
The PanTracer Liquid MolDX approval is a key catalyst for NeoGenomics’ forward-looking revenue targets. This regulatory milestone is anticipated to unlock new market opportunities and enhance the adoption of its diagnostic solutions. The company’s strategic focus on expanding its service offerings and market reach is expected to underpin the projected revenue growth through 2026.
